SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH Day	Month	Year	2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET Day	Month	Year
PRIVACY	GUATEMALA		PRIVACY		65 Years	Female	74.00 kg	15	MAY	2025

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)

Feels very sleepy / Lots of sleep [Somnolence]
Stomach pain [Abdominal pain upper]
Decay [Depressed mood]
Pain in toe due to neuropathy [Neuralgia]
Lack of appetite / No appetite [Decreased appetite]
Diarrhea [Diarrhoea]
Lethargic [Lethargy]

Case Description: This solicited case, reported by a consumer via a patient support program (PSP) conducted by a business partner, concerned a **(Continued on Additional Information Page)**

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) Abemaciclib (Abemaciclib) Tablet {Lot # D795083; Exp.Dt. MAY-2027}

20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☒ NA

15. DAILY DOSE(S)
#1) 150 mg, bid

16. ROUTE(S) OF ADMINISTRATION
#1) Oral

17. INDICATION(S) FOR USE
#1) Breast cancer (Breast cancer)

21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☒ NA

18. THERAPY DATES(from/to)
#1) 15-MAY-2025 / Ongoing

19. THERAPY DURATION
#1) Unknown

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

#1) ANASTROZOL (ANASTROZOL) Pillules ; Unknown
#2) BENICAR (OLMESARTAN MEDOXOMIL) Pillules ; 2005 / Unknown
#3) ESOMEPRAZOLE (ESOMEPRAZOLE) Pillules ; 2025 / Unknown
#4) ODICA (PREGABALIN) Pillules ; Unknown
#5) NUCLEO CMP (CYTIDINE MONOPHOSPHATE DISODIUM, URIDINE

(Continued on Additional Information Page)

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Medical Condition	Neuropathy (Neuropathy peripheral)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
Eli Lilly Interamerica Inc (AR Branch)
Tronador 4890 - Piso 12
Buenos Aires, Capital Federal CP: 1430 ARGENTINA
Phone: 54 1145464000

26. REMARKS

24b. MFR CONTROL NO.
GT202507019938

24c. DATE RECEIVED BY MANUFACTURER
17-JUL-2025

24d. REPORT SOURCE
☒ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL ☐ OTHER:

DATE OF THIS REPORT
24-JUL-2025

25a. REPORT TYPE
☒ INITIAL ☐ FOLLOWUP:

25b. NAME AND ADDRESS OF REPORTER
NAME AND ADDRESS WITHHELD.

NAME AND ADDRESS WITHHELD.

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

65-year-old female patient of an unknown origin.

Medical history included neuropathy. Concomitant medications included Olmesartan medoxomil for arterial hypertension, esomeprazole for gastric pain and pregabalin, cytidine monophosphate disodium/uridine triphosphate trisodium, both for neuropathy.

The patient received abemaciclib (Verzenio) tablet, 150 mg, twice daily, orally for the treatment of breast cancer, beginning on 15-May-2025. She also received anastrozol for breast cancer, as concomitant chemotherapy. On 15-May-2025 since starting abemaciclib therapy, she experienced diarrhea but not every day. After taking the medication, when she ate, some days she has three to four consecutive episodes of diarrhea and then had stomach pain. Somedays she had no appetite and felt very sleepy, and lethargic, some days more than others. She did not feel like getting up and just wanted to sleep. She also experienced decay/depressed mood. On 17-Jul-2025, she felt pain in her toe, which she believed was due to neuropathy (medical history). All of her events, except lethargic, were mild and required no corrective treatment. Information regarding corrective treatment for event lethargic was not provided. The outcome for the event lethargic was unknown, while the outcome of the remaining events was not recovered. The status of abemaciclib therapy was ongoing.

The initial reporting consumer did not relate the event neuropathic pain, did not provide the relatedness between the event lethargic, while related the remaining events with abemaciclib therapy.

Lilly Analysis Statement: 24-Jul-2025: The company considered the event of lethargy related to the abemaciclib.

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION continued

#5) NUCLEO CMP (CYTIDINE MONOPHOSPHATE DISODIUM, URIDINE TRIPHOSPHATE TRISODIUM) Pillules ; 2005 / Unknown